{"id":"https://openalex.org/W7216699340","doi":null,"title":"PHARMACOECONOMICS OF ORAL WEIGHT-LOWERING DRUGS IN TYPE 2 DIABETES: A COMPARATIVE STUDY OF SGLT-2 INHIBITORS AND GLP-1 ANALOGUES IN INDIA","display_name":"PHARMACOECONOMICS OF ORAL WEIGHT-LOWERING DRUGS IN TYPE 2 DIABETES: A COMPARATIVE STUDY OF SGLT-2 INHIBITORS AND GLP-1 ANALOGUES IN INDIA","alternate_titles":[],"publication_year":2025,"publication_date":"2025-08-11","ids":{"openalex":"https://openalex.org/W7216699340"},"language":"en","primary_location":{"id":"pmh:oai:ojs2.10n.324.mytemp.website:article/299","doi":null,"is_oa":true,"landing_page_url":"https://tpmap.org/submission/index.php/tpm/article/view/299","pdf_url":"https://tpmap.org/submission/index.php/tpm/article/download/299/182","source":{"id":"https://openalex.org/S4393917997","display_name":"TPM Testing, psychometrics, methodology in applied psychology","issn_l":"1972-6325","issn":["1972-6325"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","dongbi-d","norway-1","poland-40","russia-white-list-3","vabb-shw"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nd","license_id":"https://openalex.org/licenses/cc-by-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"1972-6325","raw_type":"info:eu-repo/semantics/article"},"parent_works":[],"lineage":["https://openalex.org/W7216699340"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://tpmap.org/submission/index.php/tpm/article/download/299/182","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5155016342","display_name":"SULTHAN AL RASHID1","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"RASHID, SULTHAN AL","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051401821","display_name":"Preetha Selva","orcid":"https://orcid.org/0000-0002-9345-8445","observed_orcids":["https://orcid.org/0000-0002-9345-8445"]},"institutions":[{"id":"https://openalex.org/I85461943","display_name":"Saveetha University","ror":"https://ror.org/0034me914","country_code":"IN","type":"education","lineage":["https://openalex.org/I85461943"]}],"countries":["IN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"SELVA, PREETHA","raw_affiliation_strings":["DEPARTMENT OF PHARMACOLOGY, SAVEETHA MEDICAL COLLEGE AND HOSPITALS, SAVEETHA INSTITUTE OF MEDICAL AND TECHNICAL SCIENCES, SAVEETHA UNIVERSITY, CHENNAI\u2013602105, INDIA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DEPARTMENT OF PHARMACOLOGY, SAVEETHA MEDICAL COLLEGE AND HOSPITALS, SAVEETHA INSTITUTE OF MEDICAL AND TECHNICAL SCIENCES, SAVEETHA UNIVERSITY, CHENNAI\u2013602105, INDIA;","institution_ids":["https://openalex.org/I85461943"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5154864882","display_name":"V R YASHVANTHAN","orcid":"https://orcid.org/0009-0007-2181-3886","observed_orcids":["https://orcid.org/0009-0007-2181-3886"]},"institutions":[{"id":"https://openalex.org/I85461943","display_name":"Saveetha University","ror":"https://ror.org/0034me914","country_code":"IN","type":"education","lineage":["https://openalex.org/I85461943"]}],"countries":["IN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"YASHVANTHAN, V R","raw_affiliation_strings":["DEPARTMENT OF PHARMACOLOGY, SAVEETHA MEDICAL COLLEGE AND HOSPITALS, SAVEETHA INSTITUTE OF MEDICAL AND TECHNICAL SCIENCES, SAVEETHA UNIVERSITY, CHENNAI\u2013602105, INDIA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"DEPARTMENT OF PHARMACOLOGY, SAVEETHA MEDICAL COLLEGE AND HOSPITALS, SAVEETHA INSTITUTE OF MEDICAL AND TECHNICAL SCIENCES, SAVEETHA UNIVERSITY, CHENNAI\u2013602105, INDIA;","institution_ids":["https://openalex.org/I85461943"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4319,"has_fulltext":true,"cited_by_count":1,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.5522391,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.7285000085830688,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.7285000085830688,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.2401999980211258,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0210999995470047,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pharmacoeconomics","display_name":"pharmacoeconomics","score":0.8859999775886536},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9210000038146973},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.890999972820282},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9509999752044678},{"id":"https://openalex.org/keywords/dapagliflozin","display_name":"dapagliflozin","score":0.9200000166893005},{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.9869999885559082},{"id":"https://openalex.org/keywords/drug-affordability","display_name":"drug affordability","score":0.7329999804496765},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.8270000219345093},{"id":"https://openalex.org/keywords/drug-pricing","display_name":"drug pricing","score":0.6269999742507935},{"id":"https://openalex.org/keywords/price-fluctuations","display_name":"price fluctuations","score":0.5569999814033508},{"id":"https://openalex.org/keywords/india","display_name":"India","score":0.47699999809265137}],"concepts":[{"id":"https://openalex.org/C2776738588","wikidata":"https://www.wikidata.org/wiki/Q1567856","display_name":"Pharmacoeconomics","level":2,"score":0.8914999961853027},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7818999886512756},{"id":"https://openalex.org/C23276603","wikidata":"https://www.wikidata.org/wiki/Q158230","display_name":"Pharmacoepidemiology","level":3,"score":0.42719998955726624},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.387800008058548},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35989999771118164},{"id":"https://openalex.org/C61521584","wikidata":"https://www.wikidata.org/wiki/Q705899","display_name":"Accreditation","level":2,"score":0.34940001368522644},{"id":"https://openalex.org/C2992052470","wikidata":"https://www.wikidata.org/wiki/Q31218","display_name":"Medical expenses","level":2,"score":0.328000009059906},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.2948000133037567},{"id":"https://openalex.org/C2776125615","wikidata":"https://www.wikidata.org/wiki/Q18391886","display_name":"Economic evaluation","level":2,"score":0.26030001044273376},{"id":"https://openalex.org/C524218345","wikidata":"https://www.wikidata.org/wiki/Q31218","display_name":"Health economics","level":3,"score":0.2590999901294708},{"id":"https://openalex.org/C100406419","wikidata":"https://www.wikidata.org/wiki/Q3543802","display_name":"Formulary","level":2,"score":0.25839999318122864},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.2567000091075897},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.25}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:ojs2.10n.324.mytemp.website:article/299","doi":null,"is_oa":true,"landing_page_url":"https://tpmap.org/submission/index.php/tpm/article/view/299","pdf_url":"https://tpmap.org/submission/index.php/tpm/article/download/299/182","source":{"id":"https://openalex.org/S4393917997","display_name":"TPM Testing, psychometrics, methodology in applied psychology","issn_l":"1972-6325","issn":["1972-6325"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","dongbi-d","norway-1","poland-40","russia-white-list-3","vabb-shw"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nd","license_id":"https://openalex.org/licenses/cc-by-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"1972-6325","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:oai:ojs2.10n.324.mytemp.website:article/299","doi":null,"is_oa":true,"landing_page_url":"https://tpmap.org/submission/index.php/tpm/article/view/299","pdf_url":"https://tpmap.org/submission/index.php/tpm/article/download/299/182","source":{"id":"https://openalex.org/S4393917997","display_name":"TPM Testing, psychometrics, methodology in applied psychology","issn_l":"1972-6325","issn":["1972-6325"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["anvur-scientific","dongbi-d","norway-1","poland-40","russia-white-list-3","vabb-shw"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nd","license_id":"https://openalex.org/licenses/cc-by-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"1972-6325","raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7216699340.pdf","grobid_xml":"https://content.openalex.org/works/W7216699340.grobid-xml"},"referenced_works_count":17,"referenced_works":["https://openalex.org/W1983515210","https://openalex.org/W2071874717","https://openalex.org/W2921859534","https://openalex.org/W2938583963","https://openalex.org/W2963827649","https://openalex.org/W2967960051","https://openalex.org/W2972869264","https://openalex.org/W3021305452","https://openalex.org/W3084346878","https://openalex.org/W3120821309","https://openalex.org/W3173421961","https://openalex.org/W4211057808","https://openalex.org/W4220964791","https://openalex.org/W4366684343","https://openalex.org/W4386695977","https://openalex.org/W4397033404","https://openalex.org/W4401228953"],"related_works":["https://openalex.org/W3112583620","https://openalex.org/W4413441284","https://openalex.org/W7217035096","https://openalex.org/W4403880711","https://openalex.org/W4296007721","https://openalex.org/W7170302247","https://openalex.org/W3097496809","https://openalex.org/W7167937789","https://openalex.org/W2899963016","https://openalex.org/W4386195754"],"abstract_inverted_index":{"Objective:To":[0],"assess":[1],"the":[2,14,31,113],"affordability":[3,121],"and":[4,10,22,38,45,122,138,145],"adherence":[5],"implications":[6],"of":[7,34,131],"SGLT-2":[8,43,66],"inhibitors":[9,44],"GLP-1":[11,46,91],"analogues":[12,47],"in":[13,128],"Indian":[15],"context,":[16],"with":[17,74],"a":[18],"focus":[19],"on":[20],"Pharmacoeconomics":[21],"cost":[23,55],"variations":[24],"Methods:Medication":[25],"price":[26,61,72,139],"data":[27],"were":[28,96],"collected":[29],"from":[30,48,77,101],"Current":[32],"Index":[33],"Medical":[35],"Specialties":[36],"(CIMS)":[37],"accredited":[39],"online":[40],"sources":[41],"for":[42,115,125],"January":[49],"2024":[50],"to":[51,59,80,104,119],"April":[52],"2024.":[53],"Percentage":[54],"variation":[56],"was":[57],"calculated":[58],"analyse":[60],"differences":[62],"among":[63],"brands.":[64],"Results:":[65],"inhibitors,":[67],"particularly":[68,124],"dapagliflozin,":[69],"exhibited":[70],"significant":[71],"variations,":[73,89],"costs":[75],"ranging":[76,100],"INR":[78,81,102,105],"5.9":[79],"30":[82],"per":[83,107],"tablet.":[84,108],"Combination":[85],"therapies":[86],"showed":[87],"moderate":[88],"while":[90],"analogues,":[92],"including":[93],"oral":[94],"semaglutide,":[95],"substantially":[97],"more":[98],"expensive,":[99],"294.81":[103],"387":[106],"Conclusion:":[109],"The":[110],"study":[111],"underscores":[112],"need":[114],"cost-effective":[116],"prescribing":[117],"practices":[118],"improve":[120],"adherence,":[123],"resource-constrained":[126],"settings":[127],"India.":[129],"Integration":[130],"these":[132],"drugs":[133],"into":[134],"essential":[135],"medicine":[136],"lists":[137],"regulation":[140],"could":[141],"alleviate":[142],"financial":[143],"strain":[144],"enhance":[146],"accessibility.":[147]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7216699340","counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2026-10-03T00:00:00"}
